Text Size

Examining the Usage of Dopamine Blockers in OCD Patients

This study has been completed.
Sponsor:
Information provided by:
Sheba Medical Center
ClinicalTrials.gov Identifier:
NCT00496925
First received: July 4, 2007
Last updated: January 31, 2010
Last verified: January 2010
History of Changes
  Purpose

We examine the usage of Dopamine blockers in OCD patients. We want to examine their frequency of usage, compare the course of the disease between those who receive and those who do not receive Dopamine blockers, and efficacy of the treatment.

The study will be done in two stages: 1. Collecting information the usage of Dopamine blockers from 150 OCD patients' files. 2. interviewing 60-70 patients to see the difference those who receive and those who do not receive Dopamine blockers in their current severity of disease.


Condition
Obsessive Compulsive Disorder

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Examining the Usage of Dopamine Blockers in OCD Patients

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Sheba Medical Center:

Enrollment: 63
Study Start Date: November 2007
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Outpatient and Inpatients

Criteria

Inclusion Criteria:

  • Patients over 18 years of age
  • DSM-IV diagnosis of OCD
  • Ability to understand patient information sheet, and consent to participate

Exclusion Criteria:

  • Current or past Psychotic or Bipolar disorder
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00496925

Locations
Israel
Chaim Sheba Medical Center
Ramat-Gan, Israel, 52621
Sponsors and Collaborators
Sheba Medical Center
Investigators
Principal Investigator: Joseph Zohar, MD Chaim Sheba Medical Center
  More Information

No publications provided

Responsible Party: Prof. Joseph Zohar, Chaim Sheba Medical Center
ClinicalTrials.gov Identifier: NCT00496925     History of Changes
Other Study ID Numbers: SHEBA- 07-4651-JZ-CTIL
Study First Received: July 4, 2007
Last Updated: January 31, 2010
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Obsessive-Compulsive Disorder
Compulsive Personality Disorder
Anxiety Disorders
Mental Disorders
Personality Disorders
Dopamine
Dopamine Antagonists
Cardiotonic Agents
Cardiovascular Agents
Therapeutic Uses
 Pharmacologic Actions
Sympathomimetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents

ClinicalTrials.gov processed this record on June 17, 2013